These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26244262)

  • 1. Understanding of Altitude Illness and Use of Pharmacotherapy Among Trekkers and Porters in the Annapurna Region of Nepal.
    Havryliuk T; Acharya B; Caruso E; Cushing T
    High Alt Med Biol; 2015 Sep; 16(3):236-43. PubMed ID: 26244262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in the workload of the two high altitude aid posts in the Nepal Himalayas.
    Basnyat B; Savard GK; Zafren K
    J Travel Med; 1999 Dec; 6(4):217-22. PubMed ID: 10575168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the incidence and understanding of altitude illness between porters and trekkers in the Solu Khumbu Region of Nepal.
    Newcomb L; Sherpa C; Nickol A; Windsor J
    Wilderness Environ Med; 2011 Sep; 22(3):197-201. PubMed ID: 21962045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk determinants of acute mountain sickness in trekkers in the Nepali Himalaya: a 24-year follow-up.
    McDevitt M; McIntosh SE; Rodway G; Peelay J; Adams DL; Kayser B
    Wilderness Environ Med; 2014 Jun; 25(2):152-9. PubMed ID: 24864065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features of patients with severe altitude illness in Nepal.
    Leshem E; Pandey P; Shlim DR; Hiramatsu K; Sidi Y; Schwartz E
    J Travel Med; 2008; 15(5):315-22. PubMed ID: 19006504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Awareness, prevalence, medication use, and risk factors of acute mountain sickness in tourists trekking around the Annapurnas in Nepal: a 12-year follow-up.
    Gaillard S; Dellasanta P; Loutan L; Kayser B
    High Alt Med Biol; 2004; 5(4):410-9. PubMed ID: 15671630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical problems of porters and trekkers in the Nepal Himalaya.
    Basnyat B; Litch JA
    Wilderness Environ Med; 1997 May; 8(2):78-81. PubMed ID: 11990146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute mountain sickness and ascent rates in trekkers above 2500 m in the Nepali Himalaya.
    Vardy J; Vardy J; Judge K
    Aviat Space Environ Med; 2006 Jul; 77(7):742-4. PubMed ID: 16856361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute Mountain Sickness (AMS) Knowledge Among High Altitude Marathon Runners Competing in the Everest Marathon.
    Letchford A; Paudel R; Thomas OD; Booth AS; Imray CH
    Wilderness Environ Med; 2016 Mar; 27(1):111-6. PubMed ID: 26712333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of changing trekker demographics on travel health in the Annapurna region.
    Kc B; Heydon S; Norris P
    Public Health; 2019 Mar; 168():157-163. PubMed ID: 30415826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double-blind controlled trial.
    Hillenbrand P; Pahari AK; Soon Y; Subedi D; Bajracharya R; Gurung P; Lal BK; Marahatta R; Pradhan S; Rai D; Sharma S;
    Wilderness Environ Med; 2006; 17(2):87-93. PubMed ID: 16805144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inappropriate Dexamethasone Use by a Trekker in Nepal: A Case Report.
    Haslam NR; Garth R; Kelly N
    Wilderness Environ Med; 2017 Dec; 28(4):318-321. PubMed ID: 28870508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and medical outcomes of Nepalese staff and porters compared with foreign nationals on the Annapurna trekking circuit.
    Drew CM; Colleran S; Zijp M; Lama LP; Sherpa NJ; Kelly JL; Sulzbach N; Prior D; Currin SA; Currin S; Nickol AH; Morrell MJ
    High Alt Med Biol; 2011; 12(4):349-56. PubMed ID: 22206561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Altitude Illness: Knowledge, Practice, and Attitudes of Porters in Nepal.
    Koirala P; Wolpin SE; Peterson JT
    Wilderness Environ Med; 2018 Dec; 29(4):431-436. PubMed ID: 30292563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of a Newly Constructed Motor Vehicle Road on Altitude Illness in the Nepal Himalayas.
    Reisman J; Deonarain D; Basnyat B
    Wilderness Environ Med; 2017 Dec; 28(4):332-338. PubMed ID: 28781177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review of Medical Problems in Himalayan Porters.
    Dawadi S; Basnyat B; Adhikari S
    High Alt Med Biol; 2020 Jun; 21(2):109-113. PubMed ID: 32311284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial.
    Basnyat B; Gertsch JH; Holck PS; Johnson EW; Luks AM; Donham BP; Fleischman RJ; Gowder DW; Hawksworth JS; Jensen BT; Kleiman RJ; Loveridge AH; Lundeen EB; Newman SL; Noboa JA; Miegs DP; O'Beirne KA; Philpot KB; Schultz MN; Valente MC; Wiebers MR; Swenson ER
    High Alt Med Biol; 2006; 7(1):17-27. PubMed ID: 16544963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication Use Among Mount Everest Climbers: Practice and Attitudes.
    Luks AM; Grissom C; Freer L; Hackett P
    High Alt Med Biol; 2016 Dec; 17(4):315-322. PubMed ID: 27763796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Findings of Cognitive Impairment at High Altitude: Relationships to Acetazolamide Use and Acute Mountain Sickness.
    Phillips L; Basnyat B; Chang Y; Swenson ER; Harris NS
    High Alt Med Biol; 2017 Jun; 18(2):121-127. PubMed ID: 28509579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute mountain sickness (AMS) in a Nepali pilgrim after rapid ascent to a sacred lake (4380 m) in the Himalayas.
    Thapa SS; Basnyat B
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.